What are the treatment options for pediatric variant asthma?

Childhood asthma, particularly the allergic or atopic variant often referred to as “asthma with allergic features” or “allergic asthma,” is managed using a stepwise, evidence-based approach aligned with international guidelines such as those from the Global Initiative for Asthma (GINA) and the American Academy of Pediatrics. The cornerstone of treatment involves both controller (maintenance) therapy and rescue (reliever) therapy, tailored to disease severity, frequency of symptoms, lung function, and risk of exacerbations.

For persistent symptoms—defined as daytime symptoms more than twice weekly, nighttime awakenings, or activity limitation—low-dose inhaled corticosteroids (ICS), such as budesonide or fluticasone, are the first-line controller medication. In children aged 5–11 years, ICS monotherapy remains the preferred initial maintenance strategy. For younger children (under age 5), diagnosis and management require careful clinical assessment, as objective lung function testing is often not feasible; treatment may begin with a trial of low-dose ICS if recurrent wheezing is associated with allergic sensitization, viral triggers, or a strong personal/family history of atopy.

Leukotriene receptor antagonists (e.g., montelukast) may be considered as an alternative controller in select cases—such as mild persistent asthma with prominent allergic rhinitis or exercise-induced symptoms—but they are less effective than ICS for airway inflammation control and are not recommended as first-line monotherapy. Combination inhalers containing ICS plus a long-acting beta₂-agonist (LABA) are generally reserved for children aged 12 years and older who remain uncontrolled on medium-dose ICS alone.

Short-acting beta₂-agonists (SABAs), like albuterol (salbutamol), serve as rapid-relief medications for acute bronchospasm but should not be used more than twice weekly for symptom relief—frequent use signals inadequate controller therapy and increased exacerbation risk. Notably, GINA no longer recommends SABA-only treatment for persistent asthma; instead, it advocates for ICS-containing reliever therapy (e.g., budesonide-formoterol as needed) in adolescents and adults, though this approach is not yet standard in young children due to limited pediatric data.

Non-pharmacologic strategies are integral: allergen avoidance (e.g., dust mite reduction, pet dander control), tobacco smoke cessation in the household, influenza and pneumococcal vaccination, and structured asthma education for caregivers—including proper inhaler technique, symptom recognition, and use of a written asthma action plan. Regular follow-up every 2–6 months allows for assessment of symptom control, inhaler adherence and technique, growth monitoring (especially with higher-dose ICS), and timely step-up or step-down of therapy.

In summary, optimal management of childhood asthma hinges on early, accurate diagnosis; consistent anti-inflammatory controller therapy; individualized, goal-oriented care; and shared decision-making between clinicians, families, and—when developmentally appropriate—the child.